13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001844645
Total reported value
$307.8M
$307.8M
11 檔
36.9%
As reported in its official Q1 2025 Form 13F filing, Pivotal bioVenture Partners Investment Advisor LLC's tracked investment portfolio stood at $307.8M with 11 total positions.
In Q1 2025, Pivotal bioVenture Partners Investment Advisor LLC displayed an active expansion posture, initiating 7 new positions and adding to 2 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | OCS | Oculis Holding AG | Stock-Other | 35.43% | -9.18% | +32.40% | |
| 2 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 26.84% | -0.64% | — | |
| 3 | PCVX | Vaxcyte Inc | Stock-Other | 21.72% | -1.59% | +0.98% | |
| 4 | ZBIO | Zenas Biopharma Inc | Stock-Other | 4.71% | -0.09% | — | |
| 5 | ✓ | Inozyme Pharma Inc | Stock-Other | 3.31% | — | — | |
| 6 | RXRX | Recursion Pharmaceuticals-a | Stock-Healthcare | 2.55% | +0.06% | — | |
| 7 | BIOA | Bioage Labs Inc | Stock-Other | 1.99% | +1.12% | — | |
| 8 | ✓ | Rallybio CORP | Stock-Other | 1.26% | — | — | |
| 9 | VIGL | Vigil Neuroscience Inc | Stock-Other | 0.81% | — | — | |
| 10 | IOBTQ | Io Biotech Inc | Stock-Other | 0.76% | — | — | |
| 11 | BOLT1EUR | Bolt Biotherapeutics Inc | Stock-Other | 0.61% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ARQT | Arcutis Biotherapeutics Inc | +20.7% | — | Add |
| 2 | PCVX | Vaxcyte Inc | +9.3% | +0.98% | Trim |
| 3 | ✓ | Inozyme Pharma Inc | -7.4% | — | Add |
| 4 | BOLT1EUR | Bolt Biotherapeutics Inc | -10.9% | — | Unchanged |
| 5 | ✓ | — | EXIT | Sold out | |
| 6 | OCS | Oculis Holding AG | — | NEW | New buy |
| 7 | ✓ | Akouos Inc | — | EXIT | Sold out |
| 8 | ✓ | Aligos Therapeutics Inc | — | EXIT | Sold out |
| 9 | ✓ | Fusion Pharmaceuticals Inc | — | EXIT | Sold out |
| 10 | ZBIO | Zenas Biopharma Inc | — | NEW | New buy |
| 11 | RXRX | Recursion Pharmaceuticals-a | — | NEW | New buy |
| 12 | BIOA | Bioage Labs Inc | — | NEW | New buy |
| 13 | ✓ | Rallybio CORP | — | NEW | New buy |
| 14 | VIGL | Vigil Neuroscience Inc | — | NEW | New buy |
| 15 | IOBTQ | Io Biotech Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Pivotal bioVenture Partners Investment Advisor LLC reported a total U.S. public equity portfolio value of $307.8M across 11 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including OCS, ARQT, PCVX) accounted for 36.9% of total reported equity market value during Q1 2025.
Top New Position Initiated
OCS
市值: $43.8M
Top Position Liquidated / Trimmed
前期市值: $97.2M
During Q1 2025, Pivotal bioVenture Partners Investment Advisor LLC's top holdings by market value included OCS (35.4%)、ARQT (26.8%)、PCVX (21.7%). The largest single position, OCS, represented 35.4% of total portfolio value.
In Q1 2025, Pivotal bioVenture Partners Investment Advisor LLC made 14 total portfolio adjustments, initiating 7 new buys, adding to 2 positions, trimming 1 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.